Related Experiment Video
Updated: Dec 18, 2025
07:16
An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
Published on: November 30, 2022
4.2K
ACE2 and COVID-19 and the resulting ARDS
Xiaoqing Zhang1,2, Shuren Li3, Shaoqian Niu2
1Department of Cardiology, Hebei General Hospital, Shijiazhuang, China.
Postgraduate Medical Journal
|June 12, 2020
Summary
Angiotensin-converting enzyme 2 (ACE2) plays a protective role in COVID-19-related acute respiratory distress syndrome (ARDS). Enhancing ACE2 activity or using RAS blockers may offer promising treatments for COVID-19.
Area of Science:
- Cardiovascular Research
- Infectious Diseases
- Pulmonology
Background:
- The renin-angiotensin system (RAS) comprises two counter-regulatory axes: the classical ACE-angiotensin II (Ang II)-AT1R axis and the ACE2-Ang(1-7)-Mas axis.
- ACE2 antagonizes the classical RAS axis, offering protection against lung injury.
Purpose of the Study:
- To review the correlation between ACE2 and COVID-19-induced acute respiratory distress syndrome (ARDS).
- To explore potential therapeutic strategies targeting the RAS for COVID-19 treatment.
Main Methods:
- Literature review of studies investigating the role of ACE2 in COVID-19 pathogenesis and ARDS.
- Analysis of the RAS pathways involved in viral entry and inflammatory responses.
Main Results:
- 2019 novel coronavirus (2019-nCoV) utilizes ACE2 for cell entry, potentially leading to excessive RAS activation and ARDS.
- ACE2 demonstrates a protective effect against ARDS in the context of COVID-19.
Conclusions:
- Targeting ACE2 activity or utilizing RAS blockers presents promising therapeutic avenues for managing COVID-19 and its associated ARDS.
- Further research into RAS modulation is warranted for effective COVID-19 treatment strategies.
Related Concept Videos
01:21Acute Respiratory Failure-II
893
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
893
01:21Acute Respiratory Failure-I
688
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
688
01:29Pneumonia II: Pathophysiology
2.3K
The pathophysiology of pneumonia involves the following steps:
2.3K
01:30Acute Respiratory Failure-III
637
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
637
01:29Acute Respiratory Failure-V
355
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
355
01:20COPD: Pathogenesis and Clinical Features
1.7K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.7K